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ABSTRACT 
 
An Investigation of the Role of GABAB Ligands on Cued and Contextual Fear 
Conditioning 
 
by 
 
Chelcie Faith Heaney 
 
Dr. Jefferson Kinney, Examination Committee Chair 
Assistant Professor of Psychology 
University of Nevada, Las Vegas 
 
 GABA is the primary inhibitory neurotransmitter in the brain and mediates 
several processes, including learning and memory.  Activating or inhibiting GABA 
receptors allows for the examination of the effects of altered GABAergic signaling on 
these processes.  The two main receptors, GABAA and GABAB, each have a different 
mechanism of action when activated, thus they may contribute differentially to learning 
and memory.  The metabotropic GABAB receptor responds with the activation of several 
intracellular signaling cascades, which provide long-lasting inhibitory effects that 
primarily mediate network function.   Conversely, the GABAA receptor is an ion channel 
that contributes more immediate inhibitory effects through the movement of ions across 
the cell membrane.  While there is more research regarding the role of the GABAA 
receptor in learning and memory because it was discovered first, the data on the role of 
the GABAB receptor in learning and memory are more varied and inconsistent.  Because 
of the discrepancies in the literature, it is necessary to better characterize the effects 
contributed by the GABAB receptors to learning and memory.  We examined the effects 
of a GABAB agonist (baclofen) and a GABAB antagonist (phaclofen) on the associative 
learning and memory task, cued and contextual fear conditioning, as well as the 
extinction of the learned associations.  Using two protocols that vary in complexity and 
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differentially recruit brain regions to learn the associations, we were able to evaluate 
whether the GABAB ligands produce different behavioral effects based on task in our 
first experiment.  In a second experiment, we then investigated whether the results seen in 
the previous two experiments could be attributed to how well the task was learned 
initially by delaying the onset of ligand administration.  Further, we investigated whether 
administration of the ligands altered GABA receptor protein levels in the neurological 
regions associated with the behavioral tasks.  While baclofen treatment impaired the 
extinction of both the cued and contextual fear associations in both experiments, 
phaclofen treatment did not alter the acquisition or extinction of any of the associations.  
Interestingly, we found task-dependent shifts in GABAB receptor protein levels in both 
baclofen- and phaclofen-treated animals in several brain regions.  In some instances, 
significant differences in protein levels were found in delay-trained groups that were not 
evident even in a non-significant trend in the trace-trained groups.  These protein 
differences suggest that the administration of GABAB ligands alters behavior and 
neurological protein levels in a differential manner.  Further study on both components 
(behavior and cellular effects) is warranted to help elucidate the role of GABAB receptors 
in learning and memory. 
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CHAPTER 1 
INTRODUCTION 
 The processes that underlie learning and memory are important for the survival of 
any organism.  Animals must be able to adapt based on previous experiences and also 
detect patterns in stimuli in order to avoid predators, collect food, and even battle the 
elements.  Because there are many diseases and disorders that disrupt these processes, it 
is important to understand the mechanisms by which they normally occur.  Insight into 
normal functioning may then allow the development of treatments directed at improving 
deficits in learning and memory.  There are several of types of learning (e.g. associative 
and non-associative) and memory (e.g. short-term and long-term), which makes the study 
of the mechanisms simultaneously easier (because we can focus on a single aspect of the 
process) and more difficult (because each process may rely on multiple independent 
and/or related mechanisms).    
 Of particular interest is Pavlovian cued and contextual fear conditioning, a type of 
associative learning, in which a neutral tone stimulus (conditioned stimulus, CS) is paired 
with and cues the unconditioned stimulus (US), a mild foot shock, in a particular 
environment, or context.  The US produces the unconditioned fear response (UR), which 
manifests as freezing in rodents.  Once the associations between the US and both the CS 
and context are learned and produce behavior similar to the UR, the response becomes 
the conditioned response (CR).  The strength of these associations can then be tested later 
by either presenting the CS in a novel context without the US or by returning the subject 
to the original context without the US and monitoring the proportion of time the subject 
spends expressing the CR.   
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This type of learning lends itself to being investigated experimentally because the 
associations are easily learned, readily quantifiable, and decrease over time without 
further US presentations (extinction).  Extinction is the process of learning that the 
previously learned CS or context no longer accurately predict the US; this mechanism is 
thought to be inhibitory in nature, and is not analogous to forgetting.  Further, the 
difficulty of this task, as well as the brain regions recruited to learn the associations, can 
be manipulated through procedural variation.  The two variations commonly used are 
delay and trace cued and contextual fear (CCF) conditioning.  Both procedures utilize the 
same CS and US, however in delay CCF the CS and US overlap in time, where in trace 
CCF, the stimuli are separated by a brief time interval.  It has been demonstrated that the 
trace CCF procedure is more difficult to learn than the delay CCF procedure due to this 
time interval separating the CS and US. 
 While considerable research has been conducted regarding the brain areas that 
have been shown to mediate Pavlovian learning, some of the cellular mechanisms 
responsible for the learning are less well understood.  The excitatory signaling 
component is well characterized for the cellular mechanisms that drive learning and 
memory; however, the brain also largely utilizes inhibitory signaling.  While it has not 
been as extensively investigated as excitatory signaling, inhibitory signaling may also 
play a role in learning and memory.  For instance, inhibitory systems can modulate 
excitatory processes that are known to be involved in learning and memory, such as theta 
and gamma oscillations.  Further, it has been suggested that the process of extinction may 
rely on inhibitory signaling in order to alter the previously learned associations, allowing 
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an organism to be adaptable.  The role of inhibitory systems, therefore, appears to be an 
important aspect of learning and memory, and requires further investigation.  
 
Research Questions 
In order to examine the role of altered GABAB receptor function in fear 
conditioning, we tested the effects administering two ligands, baclofen (a GABAB 
agonist) and phaclofen (a GABAB antagonist), throughout delay and trace cued and 
contextual fear conditioning (CCF) and extinction.  We also investigated whether the 
differences seen by administering the ligands throughout the entirety of the delay and 
trace CCF procedures could be, in part, due to altered acquisition of the associations.  
Finally, we examined the effects of GABAB ligand administration on GABAergic 
proteins in brain regions implicated in learning and extinguishing the associations of 
delay and trace CCF. 
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CHAPTER 2 
REVIEW OF RELATED LITERATURE 
Inhibitory Drive in the CNS – GABA 
 Gamma-aminobutyric acid (GABA) was discovered in 1950 and has since been 
characterized as the primary inhibitory neurotransmitter in the central nervous system 
(CNS; Roberts, 1956).  GABA cannot cross the blood brain barrier and must be 
synthesized in the brain via the decarboxylation of glutamate (Roberts, 1956; Olsen, 
2001; Watanabe et al., 2002).  There are two major subtypes of GABA receptors 
(GABAA and GABAB), and while the primary mechanism of activation of both receptor 
subtypes is to hyperpolarize cells, they produce this effect through very different 
mechanisms (Olsen, 2001; Watanabe et al., 2002; Enna, 2007).  The individual and 
collective action of neurons relies on periodic depolarizations and hyperpolarizations to 
generate the action potentials that are required for signaling (Hodgkin & Huxley, 1952; 
Miledi, 1967).  Hyperpolarization typically leads to inhibition because a cell generally 
requires a net positive effect on its membrane potential in order to create an action 
potential (Bean, 2007). 
 GABAA receptors are proteins that span the cellular membrane four times and 
have several distinct subunits that associate heterogeneously into pentamers (Olsen, 
2001; Enna, 2007).  The receptors can be made up of any of the subunits, but the major 
subtypes include α, β, and γ, with the bulk of the receptors being made up of at least one 
α and one β subunit (Olsen, 2001).  The composition of the subunits of the GABAA 
receptor dictates which ligands, such as barbiturates or benzodiazepines, can bind to that 
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particular receptor, in addition to determining where the receptors will be located (Olsen, 
2001; Mohler, 2009). 
 Functionally, the GABAA receptors are ligand-gated ionotropic chloride channels 
(Olsen, 2001; Enna, 2007).  An ionotropic receptor is typically activated when a ligand 
binds and causes a conformational change in the protein.  The conformational change 
creates an opening between the intra- and extracellular environments through the cell 
membrane, allowing ions to pass into or out of the cell (Olsen & Tobin, 1990).  In the 
case of GABAA receptors, as soon as GABA binds, the channel opens and chloride 
rushes into the cell (Gahwiler & Brown, 1985; Bowery, 1993; Olsen, 2001; Watanabe et 
al., 2002).  Because chloride carries a negative charge, it creates a net negative effect on 
the cell’s membrane potential, causing the cell to hyperpolarize and thus to be inhibited.  
The GABAA receptors are very fast acting because as soon as the ligand (i.e. GABA) 
binds, the channel opens immediately; however, while the mechanism of action of this 
receptor is instantaneous, the effects of these channels are very short-lived because as 
soon as the ligand is dislodged, the channel immediately closes again (Watanabe et al., 
2002).  Thus, GABAA receptors are responsible for the fast-acting inhibitory currents 
within the CNS (Hevers & Luddens, 1998; Watanabe et al., 2002).   
 GABAA receptors are generally found on postsynaptic cell membranes (Watanabe 
et al., 2002; Enna, 2007) with some presynaptic occurrences (Kullmann et al., 2005).  
While GABAA receptors are found throughout the entire CNS, there are high levels of the 
receptor located within the frontal cortex and thalamus, with lower concentrations in the 
amygdala and hippocampus (Bowery, Hudson, & Price, 1987; Chu et al., 1990; Olsen & 
Tobin, 1990; Hevers & Luddens, 1998; Enna, 2007).  Although there are generally more 
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GABAA receptors than GABAB, GABAB receptors operate via a different mechanism of 
action and typically have a stronger affinity for GABA than GABAA (Bowery, Hudson, 
& Price, 1987; Chu et al., 1990; Isaacson, Solis, & Nicoll, 1993).   
 GABAB receptors are ligand-gated metabotropic G-protein coupled receptors.  In 
contrast to an ionotropic receptor, a metabotropic receptor is not directly coupled to a 
channel; instead, when a ligand binds, the conformational change of the receptor effects a 
change in the G-protein with which it is associated (Enna, 1997; Brown & Sihra, 2008).  
G-proteins are tetramers that consist of three major subunits (α, β, and γ) that act together 
as a functional unit (Brown & Sihra, 2008).  The change in the G-protein typically results 
in the intracellular dissociation of the α subunit from the cell-membrane-bound tetramer, 
which can initiate different cascade sequences inside the cell (Brown & Sihra, 2008).  
The intracellular effects of cascade sequences can, among other cellular functions, cause 
channels to open, cause the activation of several second messenger systems, and cause 
the initiation or silencing of transcription within the nucleus (Brown & Sihra, 2008).  The 
β and γ subunits stay bound together and attached to the cell membrane, but also are 
capable of effecting changes within the cell (Brown & Sihra, 2008).  Metabotropic 
receptors are slower acting compared to ionotropic because instead of a channel pore 
immediately opening in response to a ligand binding, a cascade sequence must be 
activated by the α or β and γ subunits of the G-protein before a channel is opened (Brown 
& Sihra, 2008).  However, the effects of metabotropic receptors are long lasting 
compared to ionotropic receptors.  When the ligand is dislodged from the receptor’s 
binding site, the intracellular signal cascade persists until it is inactivated within the cell, 
unlike an ionotropic receptor.  As a part of the signal cascade, the signal transmitted by 
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the ligand is amplified and transduced within the cell (Brown & Sihra, 2008).  Thus, even 
once the ligand is dislodged and is no longer providing input from outside of the cell, the 
signal continues to propagate within the cell.  So while the GABAB receptors are 
responsible for a slow inhibitory current, the magnitude of effect is enhanced and longer 
lasting due to the signal cascade (Couve, Moss, & Pangalos, 2000; Bettler et al., 2004).   
 GABAB receptors are seven-transmembrane proteins and have two classes of 
receptor subtypes, GABAB1 and GABAB2; additionally, the GABAB1 receptor subtype 
has two isoforms, GABAB1a and GABAB1b  (Couve, Moss, & Pangalos, 2000; Bowery et 
al., 2002; Enna, 2007; Kohl and Paulsen, 2010).  The subunits couple together to form a 
heterodimer, and each subunit demonstrates a unique role to help the functioning of the 
receptor (Enna, 1997; Jones et al., 1998; Kaupmann et al., 1998; White et al., 1998; 
Villemure et al., 2005; Pinard, Seddik, & Bettler, 2010).  The main difference between 
the two GABAB1 isoforms appears to be related to the receptor’s location.  Receptors 
composed of GABAB1a/2 generally inhibit presynaptically, and should act to prevent 
neurotransmitter release, whereas those composed of GABAB1b/2 subunits appear to 
primarily inhibit postsynaptically through inhibitory postsynaptic currents (Perez-Garci et 
al., 2006; Vigot et al., 2006; Ladera et al., 2008; Kohl & Paulsen, 2010). 
 The GABAB1 subunits appear to contain the binding site for GABA, as well as for 
agonists and antagonists, whereas the GABAB2 subunits couple the receptor complex to 
G-proteins, as well as bring the heterodimer complex to the cell surface from the 
endoplasmic reticulum (Galvez et al., 2001; Robbins et al., 2001; Bowery et al., 2002; 
Kohl & Paulsen, 2010; Pinard, Seddik, & Bettler, 2010).  If two GABAB2 subunits or any 
combination of two GABAB1 subunits bind together, the resultant GABAB receptor is 
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dysfunctional.  In GABAB1-knockout mice, the typical G-protein-linked current is absent; 
GABAB2-knockout mice demonstrate “atypical GABAB1-mediated responses,” 
suggesting that GABAB1 is capable of coupling to other G-proteins in the absence of 
GABAB2 (Pinard, Seddik, & Bettler, 2010).   
 As previously alluded to, GABAB receptors are found both pre- and post-
synaptically, though there may be different mechanisms of action depending on location 
(Misgeld, Bijak, & Jarolimek, 1995; Watanabe et al., 2002; Enna, 2007; Kohl & Paulsen, 
2010).  Presynaptic GABAB receptors may be participating in a feedback loop as 
autoreceptors (Davies et al., 1991; Misgeld, Bijak, & Jarolimek, 1995; Zarrindast et al., 
2002; Kohl & Paulsen, 2010) by mediating the presynaptic release of GABA, or as 
heteroreceptors (Sakaba & Neher, 2003; Tiao & Bettler, 2007; Bowery, 2010; Kohl & 
Paulsen, 2010) by mediating the presynaptic release of other neurotransmitters such as 
glutamate (Sakaba & Neher, 2003) or acetylcholine (Morton et al., 2001).  These 
receptors appear to need strong stimulation and large amounts of GABA in the synapse in 
order to be activated, suggesting some may be located extrasynaptically (Misgeld, Bijak, 
& Jarolimek, 1995; Ladera et al., 2008; Pinard, Seddik, & Bettler, 2010). 
 Perhaps the only clear functional distinction based on location is the previously 
described auto- and heteroreceptor function that, by definition, must occur 
presynaptically.  While there appears to be a trend of certain functions based on location, 
research continually demonstrates that there are exceptions.  For instance, presynaptic 
GABAB receptors can affect neurotransmitter release by inhibiting voltage-gated calcium 
conductance in the cell membrane at the synaptic terminal (Misgeld, Bijak, & Jarolimek, 
1995; Bettler et al., 2004; Bowery, 2007; Kohl & Paulsen, 2010).  Once the GABAB 
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receptor is activated, the β and γ subunits of the G-protein dissociate from the G-protein 
complex and bind to voltage-gated calcium channels, which leads to their inactivation 
(Couve, Moss, & Pangalos, 2000; Bettler et al., 2004; Padgett & Slesinger, 2010).  A 
reduction in calcium entering the synaptic terminal (i.e. decreased calcium conductance) 
leads to decreased release of neurotransmitter from the presynaptic neuron into the 
synapse (Llinas, Steinberg, & Walton, 1981; Bean, 2007).  A decreased amount of 
neurotransmitter in the synapse then leads to decreased postsynaptic receptor activation 
because less neurotransmitter is available to bind and activate receptors.  While this may 
not necessarily lead to postsynaptic inhibition through hyperpolarization of the 
postsynaptic membrane, decreased signaling to the postsynaptic neuron sufficiently 
modifies the strength of the stimulus within the postsynaptic cell, preventing the firing or 
inhibition of an action potential, as well as possibly altering the firing rate of the 
postsynaptic neuron.   
 However, it also has been demonstrated that GABAB receptors can inhibit a 
postsynaptic cell through the decrease of calcium conductance (Misgeld, Bijak, & 
Jarolimek, 1995; Bettler et al., 2004; Kohl & Paulsen, 2010; Padgett & Slesinger, 2010).  
Like the decrease in presynaptic calcium conductance, the postsynaptic decrease can be 
achieved through the inactivation of voltage-gated calcium channels through G-protein 
coupling (Kohl & Paulsen, 2010; Padgett & Slesinger, 2010).  In the postsynaptic neuron, 
however, inhibition occurs because calcium, one of the primary depolarizing ions, is no 
longer entering the cell, thus there is a decrease in excitatory input making the initiation 
of action potentials more difficult.  So although this method can occur in the postsynaptic 
neuron, it appears to be more common presynaptically (Bettler et al., 2004). 
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 In addition to inactivating voltage-gated calcium channels, a GABAB receptor can 
activate an inward-rectifying potassium channel (Dascal, 1997; Mark & Herlitze, 2000; 
Brown & Sihra, 2008).  The inward-rectifying potassium channel is activated by the 
dissociated β and γ subunits of the G-protein complex (Dascal, 1997; Brown & Sihra, 
2008; Padgett & Slesinger, 2010), which increase potassium conductance.  Potassium 
then effluxes out of the cell, leading to hyperpolarization (Bettler et al., 2004; Pinard, 
Seddik, & Bettler, 2010).  While the effects of GABA and inward-rectifying potassium 
channels are more typically found in postsynaptic sites (Luscher et al., 1997; Yamada, 
Inanobe, & Kurachi, 1998; Mark & Herlitze, 2000; Bettler et al., 2004), recent research 
suggests that these channels may also help to regulate neurotransmitter release 
presynaptically (Ladera et al., 2008; Fernandez-Alacid et al., 2009).  The presynaptic 
inward-rectifying potassium channels may work by limiting the amount of calcium that is 
allowed to enter the neuron by altering the duration of an action potential by 
counteracting the depolarization with an efflux of potassium (Ladera et al., 2008). 
 Finally, in addition to modulating specific channels, GABAB receptors also may 
act by inhibiting adenylyl cyclase (Bettler et al., 2004; Enna, 2007; Padgett & Slesinger, 
2010).  The α subunit dissociates from the G-protein complex and inhibits adenylyl 
cyclase, which normally initiates a number of other intracellular cascades, including 
those that affect short- and long-term memory (Birnbaumer, 2007; Brown & Sihra, 2008; 
Vianna et al., 2000; Padgett & Slesinger, 2010).  This mechanism of action may be 
present at both pre- and postsynaptic neurons, as it has been suggested that the cyclic 
adenosine monophosphate (cAMP) cascade (which is activated by adenylyl cyclase) may 
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play a role in synaptic signaling via neurotransmitter release, and neuronal excitation 
(Ulrich & Bettler, 2007; Padgett & Slesinger, 2010).   
 While all of these mechanisms of action (decreased calcium conductance, 
increased potassium conductance, and inhibition of adenylyl cyclase) have been 
discussed separately, they could work in conjunction with each other.  For instance, 
because the α subunit works independently of the β and γ subunits, activation of the 
GABAB receptor complex could lead to the inhibition of adenylyl cyclase and decreased 
calcium conductance or increased potassium conductance, or even all three, at the same 
time.  Because the juxtaposition of these mechanisms would be an additive inhibitory 
effect, one can see how the magnitude of the effect of an activated GABAB receptor is 
more robust than that of a GABAA receptor. 
 GABAB receptors are located throughout the entire CNS, and appear to have a 
high concentration in the frontal cortex, lateral amygdala, and the thalamus (Bowery, 
Hudson, & Price, 1987; Chu et al., 1990).  Additionally, moderate levels of GABAB 
receptors are present in the hippocampus (Bowery, Hudson, & Price, 1987; Chu et al., 
1990).  As previously mentioned, GABAB receptors appear to have a higher binding 
affinity for GABA than GABAA receptors, which could explain the decreased number of 
GABAB receptors compared to GABAA receptors (Isaacson, Solis, & Nicoll, 1993).  
When a receptor has a higher affinity for a substrate, the substrate is more attracted to, 
and more likely to bind to, the high-affinity receptor than any other receptor.  Therefore, 
fewer high affinity receptors are necessary to gain a particular effect since they are likely 
to bind the substrate faster than and before other receptors.  Low affinity receptors would 
then need to compete with the higher affinity receptors, and may do so with increased 
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numbers.  Alternatively, because GABAB receptors have a larger and more prolonged 
effect compared to GABAA receptors, fewer GABAB receptors may be needed to have a 
comparable effect.  Further, having an increased number of high affinity receptors could 
lead to excessive signaling that would disrupt normal functioning. 
 
GABA in Learning and Memory 
 Long-term potentiation (LTP) and synchronous neural firing (gamma and theta 
wave oscillations) have been implicated in facilitating learning and memory formation.  
LTP is the strengthening of synaptic connections between two or more neurons that fire 
simultaneously (Hebb, 1949; Bliss & Lomo, 1973; Bliss & Collingridge, 1993), and 
though it is most well characterized in the hippocampus (Malenka & Bear, 2004), the 
process also occurs in the amygdala and elsewhere (Herry & Garcia, 2002; Sigurdsson et 
al., 2007).  Altering GABAergic tone is capable of affecting LTP (Davies et al., 1991; 
Staubli, Scafidi, & Chun, 1999; Trepel & Racine, 2000).  Administering GABAA or 
GABAB antagonists to hippocampal slices increases the magnitude of LTP (Olpe & 
Karlsson, 1990; Steele & Mauk, 1999), whereas GABAA agonists decrease LTP 
induction (Blitzer, Gil, & Landau, 1990; Steele & Mauk, 1999; Fujii et al., 2000).   
 While several neurotransmitters play a role in regulating oscillations 
(Boguszewicz et al., 1996), GABAergic interneurons are important to the formation and 
entrainment of gamma and theta wave oscillations (Gonzalez-Burgos, 2010).  
GABAergic interneurons can also modulate oscillations by altering the frequency and 
amplitude of inhibitory postsynaptic currents (Henderson & Jones, 2005).  Decreasing the 
effects of GABA through antagonism enhances theta and gamma wave oscillations 
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(Konopacki et al., 1997; Leung & Shen, 2007), whereas increasing GABAergic effects 
using agonists reduces theta and gamma wave oscillations (Bland & Oddie, 2001; Brown, 
Davies, & Randall, 2007).   
High frequency stimulation can induce LTP (Bliss & Collingridge, 1993; Tang et 
al., 1999), and while the high frequencies used in vitro are uncommon in vivo, 
synchronous oscillations that are commonly observed in the CNS are sufficient to 
modulate LTP (Orr et al., 2001; Axmacher et al., 2006; DeCoteau et al., 2007; Jutras & 
Buffalo, 2010).  In fact, oscillations correlate with memory encoding (Klimesch, 1999; 
DeCoteau et al., 2007; Sederberg et al., 2007).  Further, research demonstrates that 
inhibiting LTP (Davis, Butcher, & Morris, 1992; Balschun & Wetzel, 2002) or 
oscillations (Hosseinzadeh et al., 2005) is detrimental to learning and memory. 
 Because GABAergic tone can affect both LTP and synchronous network activity, 
which both affect learning and memory, GABAergic tone likely also affects learning and 
memory.  What remains to be clearly elucidated are the discrete roles of the GABA 
receptors in learning and memory. 
 The alteration of GABAergic tone by either GABAA or GABAB ligands does 
affect how an animal learns a task.  Consistent with the data above regarding GABAA 
ligands and LTP, the administration of GABAA agonists typically produce impaired 
learning and memory (Castellano, Cabib, & Puglisi-Allegra, 1996; Majchrzak & Di 
Scala, 2000; Chapouthier & Venault, 2002; Myhrer, 2003), and GABAA antagonists and 
inverse agonists enhance learning and memory (Castellano, Cabib, & Puglisi-Allegra, 
1996; Chapouthier & Venault, 2002; Myhrer, 2003; Collinson et al., 2006).  A similar, 
yet inconsistent, pattern of impaired learning and memory has been found with GABAB 
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agonists in some studies (Castellano, Cabib, & Puglisi-Allegra, 1996; McNamara & 
Skelton, 1996; Myhrer, 2003; Stuchlik & Vales, 2009) and enhanced learning and 
memory after administering GABAB antagonists (Castellano, Cabib, & Puglisi-Allegra, 
1996; Getova & Bowery, 1998).  However, the results from GABAB investigations are 
not well replicated and are, at times, contradictory.  In a review by Myhrer (2003), four 
studies attempting to demonstrate the effects of baclofen (a GABAB agonist) on the same 
passive avoidance task found that baclofen improves, impairs, and does not alter 
performance.  Since these four studies utilized the same task in the same manner and all 
administered baclofen systemically, the differing results could be due to the dosages or 
strain of animal used (Castellano, Cabib, & Puglisi-Allegra, 1996; Myhrer, 2003). 
 Few studies have utilized GABAB antagonists in specific learning and memory 
tasks, and there are inconsistent results among those studies that have been conducted, as 
well.  For instance, Mondadori, Mobius, and Borkowski (1996) administered a GABAB 
antagonist after a passive avoidance task and found enhanced memory (as measured by 
increased step-through latencies to enter the darkened chamber associated with a mild 
foot shock) for the task.  However, Zarrindast et al. (2002) also administered a GABAB 
antagonist after a passive avoidance task and found no effect on step-through latencies at 
low doses, whereas animals administered high doses actually demonstrated impaired 
performance in the task by stepping through to the shock-associated chamber faster than 
controls.  Differences between these two studies include route of administration (systemic 
versus intracranial), gender of the animals, and type of animals used (mice versus rats).  
Ultimately, these discrepancies in both the GABAB agonist and antagonist literature 
demonstrate that the effects of the GABAB receptors need to be better characterized.  
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Additionally, the relationship between dose and effect may be very different between 
agonists and antagonists; in other words, the same concentration of an antagonist and an 
agonist may not produce the same “amount” of facilitation or loss of function as it relates 
to learning and memory.  
 In addition to the inconsistencies described above, the task used can also affect 
the results.  For instance, Brucato et al. (1996) demonstrated that a single GABAB 
antagonist, while capable of suppressing the induction of LTP in the dentate gyrus, 
altered behavior in only one of the three tasks used to measure spatial learning.  The task 
that did show altered behavior was a water maze task, whereas the other two tasks were 
variations on the eight-arm radial maze.  Using GABAB ligands may possibly alter 
GABAergic tone differentially based on the task used, and some tasks may be more or 
less sensitive to a specific dose.  It is also possible that altering GABAergic tone by way 
of GABAB ligands only affects specific types of memory.  Because the tasks described 
above all produced differing results, it is important to continue characterizing the role of 
the GABAB receptors in learning and memory. 
 
GABA in Pavlovian Conditioning 
 We used Pavlovian fear conditioning, a task with well-defined neuronal regions 
associated with learning the procedure.  This task can be modified to increase how 
difficult it is to learn the associations; further, while the procedural variants rely on the 
same underlying neuronal regions, each variant recruits the brain regions differentially to 
learn the associations (Makkar, Zhang, & Cranney, 2010).  In Pavlovian fear 
conditioning, an unconditioned stimulus (US; e.g. a shock) is paired with a conditioned 
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stimulus (CS; e.g. a tone), and an association between the two is made (Pavlov, 1960).  
The unconditioned response (UR; e.g. fear), which is elicited naturally from the US, 
becomes associated with the initially neutral CS; that is, after Pavlovian conditioning, 
presenting the CS alone is capable of producing the conditioned response (CR, which is 
almost always the same behavior elicited by the UR).  An interesting aspect of this task is 
that is it possible to experimentally measure the extinction of the associations, as 
evidenced by decreased behavioral responses to a CS presentation.   
 Extinction occurs when the CS is repeatedly presented in the absence of the US, 
overriding the previously learned association that the CS always predicts the US (Bouton 
et al., 2006; Myers & Davis, 2007).  This process is not simply forgetting the association, 
however, as demonstrated by spontaneous recovery.  Spontaneous recovery is marked by 
the sudden reinstatement of the CR without additional CS-US pairings after a period of 
time wherein the CR had previously decreased over time with continual CS exposure (i.e. 
extinction occurs) (Myers & Davis, 2002; Bouton et al., 2006).  If extinction were 
indicative of forgetting, then the association should not be able to be recovered.  Instead, 
extinction is thought of as the formation of a new memory that is proposed to inhibit the 
previously acquired CS-US association (Bouton, 2004), and GABAergic 
neurotransmission is likely to play a crucial role in this change (Akirav & Maroun, 2007). 
 Pavlovian conditioning involving a tone that occurs in a specific context and 
predicts (or cues) a mild foot shock is called cued and contextual fear (CCF) conditioning 
(Phillips & LeDoux, 1992).  As the name implies, there are two main aspects to the task; 
the cued fear is elicited from the tone (CS), and the contextual fear is elicited from being 
in the original context (or environment) of the CS-US pairings (Phillips & LeDoux, 
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1992).  This task allows the investigation of the association between the CS and the US 
(cued fear), as well as the association between the US and the original context in which 
the US was presented (contextual fear).  Each association differentially relies on distinct 
brain regions, however the formation of each association is dependent upon the training 
protocol used.  The traditional protocol is called delay CCF conditioning; in this version, 
the CS and US overlap in time and co-terminate; that is, the US is presented during the 
same time that the CS is being presented.  Because the CS and US overlap, this 
association is simple and easy to learn.  Studies demonstrate that in order for an animal to 
exhibit cued fear when trained using delay CCF conditioning, an intact amygdala is 
required, whereas contextual fear depends on the hippocampus (Phillips & LeDoux, 
1992; Kim & Jung, 2006; Curzon, Rustay, & Browman, 2009; Makkar, Zhang, & 
Cranney, 2010).  
 In another variation called trace CCF conditioning, a time interval is inserted 
between the termination of the CS and onset of the US; that is, the CS and US do not co-
terminate, nor do they overlap in time.  As in delay CCF conditioning, previous research 
demonstrates that fear associated with the CS is mediated by the amygdala (Curzon, 
Rustay, & Browman, 2009; Makkar, Zhang, & Cranney, 2010); however, the time 
interval between stimuli requires hippocampal processing in order for the association 
between the CS and US to be formed (Beylin et al., 2001).  Animals with hippocampal 
lesions exhibited a drastic decrease in freezing behavior to the CS in a trace cued fear 
conditioning task compared to control animals, thus demonstrating that the hippocampus 
is involved in processing this temporal gap between CS and US (Beylin et al., 2001).  
Further, Beylin et al. (2001) demonstrated that for control animals, the longer the interval 
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is between the CS and US, the more difficult the association was to learn; the amount of 
freezing demonstrates the strength of the learned association, and longer trace intervals 
produced less freezing.  Trace conditioning does not affect contextual fear since altering 
the CS-US overlap does not change all of the environmental cues, thus the hippocampus 
still mediates contextual fear as in delay CCF (Curzon, Rustay, & Browman, 2009).   
 The brain regions involved in Pavlovian conditioning have been demonstrated to 
involve the CS-activation of the amygdala, which in turns leads to the CR, behaviorally 
(Quirk et al., 2003; Pare, Quirk, & Ledoux, 2004; Kim & Jung, 2006; Hartley & Phelps, 
2010; Makkar, Zhang, & Cranney, 2010).  This association is aided by inhibitory 
circuitry in the amygdala via control the formation of fear memories (Bolshakov, 2009; 
Ehrlich et al., 2009).  Information is thought to be sent to the hippocampus, which leads 
to the acquisition and initial storing of the contextual fear memory; additionally, 
information about the expression of fear in relation to the context may be routed from the 
hippocampus through to the amygdala (Hobin, Ji, & Maren, 2006; Kim & Jung, 2006; 
Hartley & Phelps, 2010; Makkar, Zhang, & Cranney, 2010).  Finally, the prefrontal 
cortex has been recently implicated in extinction learning due to its inhibitory projections 
between the amygdala and hippocampus (Kim & Jung, 2006; Quirk & Mueller, 2008; 
Hartley & Phelps, 2010; Makkar, Zhang, & Cranney, 2010).  Interestingly, a high 
abundance of GABAA and GABAB receptors are located in the areas just discussed 
(Bowery, Hudson, & Price, 1987). 
 Several studies have demonstrated that altered GABAergic tone in these 
structures can affect Pavlovian conditioning.  Most notable is that a GABAA agonist, 
muscimol, is commonly used to reversibly inactivate different brain regions associated 
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with conditioned fear.  For instance, Wilensky, Schafe, & LeDoux (2000) infused 
muscimol into the lateral amygdala in order to demonstrate that inactivating the amygdala 
blocks acquisition, but not the consolidation, of Pavlovian conditioning.  McEown & 
Treit (2010) infused muscimol into the ventral or dorsal hippocampus either pre- or post-
training of a conditioned fear task.  Inactivating the ventral hippocampus before training 
impaired the acquisition of the conditioned fear task as demonstrated by animals failing 
to freeze throughout training in response to continual CS-US pairings, whereas 
inactivating the dorsal hippocampus post-training impaired retention as demonstrated by 
animals failing to freeze to the CS 24 hours later (McEown & Treit, 2010).  Finally, 
Akirav, Raizel, & Maroun (2006) infused muscimol into the prefrontal cortex in order to 
investigate the effects on extinction.  The authors suggest that the GABAA agonist 
enhanced extinction; while this interpretation is debatable considering the experimental 
animals never initially demonstrated behavior similar to the control animals, it is 
important to note that the ligand did actually alter the experimental animals’ behavior.   
 Numerous studies also have investigated the role of GABA ligands in Pavlovian 
conditioning per se, although a preponderance of the studies are done using GABAA 
ligands or specific GABAA receptor subunit mutants (see Makkar, Zhang, & Cranney, 
2010).  As demonstrated earlier with other learning and memory tasks, the GABAA 
antagonists tend to improve learning and memory and GABAA agonists impair learning 
and memory.  Improvements or deficits caused by GABAA alterations are thought to 
occur by either shutting down specific brain regions or allowing the regions to be more 
active than typically observed.  Though the effect of altering GABAA receptor function 
has been extensively evaluated, there are fewer data regarding the role of GABAB 
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receptors and how longer-lasting changes to neuronal functioning may affect learning and 
memory in Pavlovian conditioning. 
 The current data regarding the role of GABAB receptors in Pavlovian 
conditioning are rather inconclusive.  For instance, Jacobson et al. (2006) used GABAB1 
receptor knockout mice in a conditioned taste aversion task, a type of Pavlovian 
conditioning.  In this task, animals were introduced to saccharine-flavored water, which 
rodents typically enjoy due to its sweetness and will drink more of compared to 
unflavored water.  The mice were later injected with lithium chloride, which made the 
animals feel sick, every time they were given the saccharine-sweetened water.  The 
animals soon learn to associate feeling ill with the saccharine-flavored water and learn to 
stop drinking this preferred water.  As previously mentioned, there are two isoforms of 
GABAB1 receptors, GABAB1a (thought to localize presynaptically) and GABAB1b 
(thought to localize postsynaptically); each receptor subunit isoform create a heterodimer 
with the GABAB2 receptor.  Interestingly, the GABAB1a knockouts were impaired in 
acquiring the taste aversion, as demonstrated by a lack of decreased ingestion of the 
saccharine-flavored water, while the GABAB1b knockouts were impaired in the extinction 
of the aversion, as demonstrated by a lack of decreased aversion to the saccharine-
flavored water in absence of the lithium chloride-induced malaise over time (Jacobson et 
al., 2006).   
 Shaban et al. (2006) also utilized GABAB1 receptor knockout mice, but instead 
used a cued fear conditioning task.  Animals were presented with two tones, only one of 
which was paired with a shock.  Wild-type animals were able to discriminate between the 
two tones and only exhibited freezing behavior (i.e. the CR) to the tone that had been 
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paired with the shock.  GABAB1a knockout animals, however, froze to both tones, 
demonstrating an over-generalization of fear, or an inability to learn the association 
specific to the CS paired with the US; the GABAB1b knockout animals were unable to 
acquire the task at all, as demonstrated by a lack of freezing to either of the tones used in 
the task (Shaban et al., 2006).  These results do not correspond to those of Jacobson et al. 
(2006) who found that the GABAB1a knockouts had difficulty acquiring the task.  This 
discrepancy could perhaps be explained by the amount of stress each task induces 
(Brucato et al. 1996).  However, more data are needed to elucidate the role of these 
receptors in Pavlovian conditioning.  While knockout studies provide some insight to the 
function of the receptors, the utilization of GABAB ligands can provide valuable 
information pertaining to the effect that altered signaling of the receptors has on learning 
and memory. 
 Based on the differences in function, discrepancies in the behavioral data between 
GABAA and GABAB receptors, and the inconsistencies within the GABAB literature 
described above, a thorough investigation of the role of GABAB receptors in a precise 
learning and memory task is warranted.  By being able to utilize training variations that 
recruit discrete brain regions where high concentrations of the receptor may indicate that 
GABAB function may be particularly relevant, cued and contextual fear conditioning is a 
task that may help provide crucial information regarding alterations of GABAB receptor 
tone on learning.  With these issues in mind, the following experiments were conducted 
in order to help clarify the role of GABAB receptors in learning and memory and 
extinction.    
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Hypotheses and Implications 
 Based on the previous research that indicate altered inhibition via GABAA 
receptors in learning and memory, we predicted that the GABAB agonist, baclofen, would 
impair the acquisition of the fear conditioning, but that it would enhance the extinction of 
the learned fear.  Alternatively, we hypothesized that the GABAB antagonist, phaclofen, 
would impair the acquisition as well as the extinction of the conditioned fear.  Because 
the trace CCF protocol is more difficult to learn and is mediated by a more complex 
network of neurological regions, we predicted that any deficits or enhancements caused 
by the GABAB ligands would be more pronounced in trace CCF as compared to delay 
CCF.  We further hypothesized that any effects of the ligands on protein levels would be 
more prominent in the trace-conditioned animals than the delay-conditioned groups.  
Specifically, we predict to see a decrease in receptor protein levels in the baclofen-treated 
animals because an agonist should down-regulate proteins; and we predicted to see an up-
regulation in protein levels in the phaclofen-treated animals because an antagonist should 
up-regulate proteins.  Based on any behavioral deficits seen, we should see corresponding 
protein changes in the brain regions that mediate the disrupted behaviors. 
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CHAPTER 3 
MATERIALS AND METHODS 
Subjects 
 One hundred and twenty male Sprague-Dawley rats (Harlan, Indianapolis, IN) 
approximately three months of age and weighing 250-300g were used.  Rats were housed 
in a temperature and humidity controlled facility (22 ± 1° C), and food and water were 
provided ad libitum.  Animals were housed in pairs and kept on a 12:12 light:dark cycle, 
lights on at 7:00am.  All procedures were approved by the Institutional Animal Care and 
Use Committee and followed NIH guidelines. 
 
Drug Treatments 
 R(+)-Baclofen hydrochloride (Sigma-Aldrich, St. Louis, MO) was dissolved in 
0.9% physiological saline vehicle at a concentration of 2mg/mL.  Phaclofen (Sigma-
Aldrich) was dissolved in 0.9% physiological saline vehicle at a concentration of 
0.3mg/mL.  Compounds were administered via intraperitoneal (i.p.) injection 15 minutes 
before behavioral testing at a volume of 1ml/kg; 0.9% physiological saline was 
administered as a control also at a volume of 1ml/kg.  Animals were randomly assigned 
to one of three treatment groups (saline, baclofen, or phaclofen administration; n=10) in 
one of two experiments (drug administration given through delay or trace cued and 
contextual fear (CCF) conditioning, or drug administration starting on Day 2 of delay or 
trace CCF conditioning; for a total of n=30 per experiment).  Each experiment contained 
the same treatment groups, but an individual animal only participated in one experiment.  
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Cued and Contextual Fear Conditioning 
 Fear conditioning training and contextual fear testing were conducted in a 10” x 
10” x 7.5” acrylic chamber (San Diego Instruments, San Diego, CA).  The floor of the 
chamber consisted of a stainless steel grid made of 1/4” grids spaced at 9/16”.  In 
between animals, the chamber was cleaned using a common household cleaner, Formula 
409 (Clorox Company, Oakland, CA).   
 Cued fear testing was conducted in an altered context chamber that consisted of 
17” x 10.5” x 5” opaque plastic.  In addition to differences in material, shape, and height 
from the floor (because the altered context chamber has tall opaque walls, the chamber 
was placed on the floor instead of a table in order to observe animal behavior), a novel 
scent cue (vanilla extract) was added to one of the walls.  The chamber was cleaned 
between animals using a 1% ethanol solution to ensure no olfactory overlap with the 
training chamber. 
 Trials were programmed and run with Freeze Monitor (San Diego Instruments) 
using a Cobalt Instruments computer.  Two researchers visually monitored the animals’ 
freezing behavior and recorded the data manually.  The data collected for each animal 
included whether the animal was freezing (determined every 10 seconds), as well as a 
qualitative description of the behavior exhibited by the animal if it was not freezing (e.g. 
grooming, rearing, sniffing, walking, moving head). 
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Behavioral Testing  
Experiment 1 – GABAB Ligands Administered Throughout Cued and Contextual Fear 
Conditioning 
Delay CCF Conditioning Protocol 
Fifteen minutes prior to testing, animals received an i.p. injection of either saline, 
baclofen, or phaclofen.  Subjects were taken from the colony room individually to a 
dedicated testing room containing the fear conditioning chamber (which doubled as the 
contextual fear testing chamber) or the cued fear testing chamber, a table upon which the 
fear conditioning chamber was placed, a computer desk, and chairs. 
 For delay cued and contextual fear conditioning (Day 1), the animals were placed 
into the fear conditioning chamber and allowed to explore the chamber for two minutes.  
After the two-minute acclimatization period, the conditioned stimulus (CS), a 2.9kHz 
88dB tone, was presented for 30 seconds.  One second before the CS terminated, a one 
second unconditioned stimulus (US), a 0.5mA foot shock, was delivered and co-
terminated with the conditioned stimulus.  For a visual representation of this procedure, 
please see Figure 1.  Once both the CS and US terminated, the animals were given 
another two minutes to explore the chamber.  The CS-US pairing was presented once 
more, for a total of two pairings.  The animals were given a final two minutes in the 
chamber.  Freezing behavior was recorded during the first and last two minutes of the 
training session by visual inspection by researchers every 10 seconds.  At the end of the 
training session, the animals were taken back to their home cage.   
 On Day 2, 24 hours post-training, the animals underwent a cued fear test session.  
They again received an i.p. injection 15 minutes before testing.  Animals were taken from 
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the colony room to the dedicated testing room and placed into the altered context 
chamber.  Animals were given two minutes to explore the altered context chamber; after 
the two-minute exploration, the CS was presented for one minute.  The animal had 
another two minutes to explore before the CS was presented again.  The CS was 
presented in this manner for a total of four presentations during the cued fear test session 
and freezing behavior was recorded during the entire session by researchers every 10 
seconds.  Once the cued fear test session was over, the animal was returned to its home 
cage.  
 On Day 3, 48 hours post-training, the animals underwent a contextual fear test 
session.  They received an i.p. injection fifteen minutes prior to behavioral testing.  
Animals were taken to the dedicated testing room and placed into the original 
conditioning chamber for the contextual fear test session.  The animals remained in the 
chamber for 10 minutes; neither the CS nor the US were presented during this time.  Data 
was collected in an identical fashion as previous days and at the end of the contextual fear 
test session, the animals were returned to their home cage.  
 Cued fear test and contextual fear test sessions were repeated once more over 
successive days; test sessions were performed as described above, including i.p. 
injections.  A reminder trial occurred immediately after the 10-minute contextual fear test 
session on Day 5 and consisted of a single presentation of the 30-second CS co-
terminating with the one-second US.  Behavior was monitored for freezing during the 10-
minute contextual fear test session, during the presentation of the CS, as well as two 
minutes after the end of the reminder trial; freezing was recorded by researchers every 10 
seconds.   
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 Cued and contextual fear were tested 24 and 48 hours (respectively) post-
reminder in the same manner as described above, including i.p. injections. 
 
Trace CCF Conditioning Protocol  
 All conditions and procedures were identical to those in Experiment 1 except for 
the following changes.  For initial training on Day 1, instead of co-terminating with the 
30 second tone, the one second 0.5mA shock was presented 2.5 seconds after the 
conditioned stimulus terminated.  For a visual representation of this procedure, please see 
Figure 1.  Additionally, instead of two tone-shock presentations, the animals received a 
total of four tone-shock pairings because previous research has established that this CCF 
variation is more difficult to learn.   The remainder of the protocol followed exactly the 
same as described for the Delay CCF conditioning protocol, except the reminder trial 
consisted of the 30-second conditioned stimulus, followed 2.5 seconds later by the one-
second unconditional stimulus.  
 
 
 
Figure 1.  Visual Representation of Delay and Trace CCF Conditioning Protocols 
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Experiment 2 - GABAB Ligands Administered After Cued and Contextual Fear 
Conditioning Training 
Delay CCF Conditioning Protocol 
 This experiment proceeded exactly like Experiment 1 Delay CCF Conditioning 
Protocol, with the exception that no drugs were administered on Day 1.  Animals 
received i.p. injections 15 minutes before testing on all subsequent days. 
 
Trace CCF Conditioning Protocol 
 This experiment proceeded exactly like Experiment 1 Trace CCF Conditioning 
Protocol, with the exception that no drugs were administered on Day 1.  Animals 
received i.p. injections 15 minutes before testing on all subsequent days.  For this portion 
of the experiment, the data of one baclofen animal was removed due to complications 
during the experiment, so saline n=10, baclofen n=9, and phaclofen n=10 
 
Sensory and Analgesia Testing 
 In order to determine that the ligands administered to the animals did not alter 
sensorimotor functioning, nor produced an analgesic effect that could bias the measures 
of learning and memory, we conducted basic sensory and nociceptive tests on all groups.  
All control tests were completed 15 minutes after i.p. injections of the ligands 
administered during the cued and contextual fear procedures. 
 First, the animals were tested for their ability to respond to auditory stimuli.  We 
tested startle amplitude using a chamber and the Startle software from San Diego 
Instruments (San Diego, CA); each group’s startle response to 10ms white noise bursts 
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presented at 90, 100, 110, and 120dB was evaluated.  This test was done 24 hours after 
the completion of the fear conditioning procedure. 
 After testing auditory functioning, we evaluated nociceptive sensitivity to ensure 
that the administered ligands did not produce an analgesic effect that may have altered 
learning and memory performance via a tail flick test.  This procedure consisted of using 
water heated to 55°C and then placing the tip of the animal’s tail into the water.  This test 
has been used extensively to determine alterations in pain threshold without inducing any 
damage since the animals rapidly “flick” their tail from the water.  Two researchers timed 
and recorded the latency for the animal to remove or “flick” its tail from the heat. 
 
Tissue Collection 
 Fifteen minutes after the tail flick test, the animals were euthanized by CO2 
asphyxiation.  Tissue was collected immediately afterwards.  The animals had their 
frontal cortices, amygdalae, hippocampi, and cerebella dissected out.  The tissue later 
underwent SDS-PAGE western blotting.  
 
SDS-PAGE Western Blotting 
  Cortices, amygdalae, hippocampi, and cerebella were collected from rats by 
dissection and then flash-frozen in dry ice and stored at -80°C.  Tissue was homogenized 
using RIPA buffer (20mM Tris-HCL (pH 7.5), 150mM NaCL, 1mM Na2EDTA, 1mM 
EGTA, 1% NP-40, 1% sodium deoxycholate, 2.5mM sodium pyrophosphate, 1mM β-
glycerophosphate, 1mM Na3VO4, 1µg/ml leupeptin) from Cell Signaling (Danvers, MA) 
with 1mM DTT, 1mM PMSF, 20µg/ml aprotinin, and 0.1% SDS added.  
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Homogenization was performed using a handheld Polytron (Kinematica Inc., Lucerne, 
Switzerland) tissue homogenizer.  Tissue was then vortexed and centrifuged for 15 
minutes at 15,000 x g at 4°C.  The supernatant was collected and used to determine 
protein concentration via a bicinchoninic acid assay (BCA, Pierce, Rockford, IL). 
 Once sample concentration was known, all tissue was run via SDS-PAGE 
(Laemmli, 1970).  Samples were loaded at a concentration of 20µg; samples contained 
protein from the sample of interest, a Laemmli buffer containing 1% SDS (BioRad, 
Hercules, CA), and distilled water for a total volume of 10µL.  Samples were heat 
denatured at 100°C for five minutes, then buried on ice for five minutes before being 
loaded on an acryl gel.  The gels were run on ice for 60 minutes at a constant 0.04A.  
Once the run was complete, the protein was transferred to a nitrocellulose membrane for 
one hour on ice at a constant current of 0.25A.  Once the transfer was complete, the 
membranes blocked for two hours in blocking buffer (1x Tris-buffered saline with 0.05% 
Tween-20 (TBST), 5% BSA, and 0.01% NaN3).  The membranes were then incubated in 
5% BSA TBST with a primary antibody (e.g. GABAB1a/b, GABAB2) dilution overnight at 
4°C.  The next morning, after a 30-minute warming-up period, the membranes were 
washed with TBST for 10 minutes, three times, for a total of 30 minutes.  The 
membranes then were incubated in 5% milk TBST with the appropriate peroxidase-
labeled secondary antibody for about 1.5 hours.  After another 30-minute wash in TBST, 
the membranes were exposed to Amersham ECL Plus (GE Healthcare Life Sciences, 
Piscataway, NJ) and imaged using a Typhoon 9410 Variable Mode Imager (GE 
Healthcare Life Sciences).  Protein quantities were analyzed using ImageQuant 5.2 
software (GE Healthcare Life Sciences). 
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Statistical Analyses 
 Analyses were performed using SPSS.  Data from Day 1 (training) were analyzed 
using paired t-tests and data from the reminder trial on Day 5 were analyzed using 
analysis of variance (ANOVA).  Repeated measures ANOVA were run on data from all 
cued and contextual extinction sessions after both training and reminder.  Data from 
startle amplitudes, tail flick latencies, and western blot analyses were also analyzed via 
ANOVA.  Tukey post-hoc comparisons were performed following a significant result 
where applicable.   
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CHAPTER 4  
RESULTS 
Experiment 1 – GABAB Ligands Administered Throughout Cued and Contextual Fear 
Conditioning 
Cued and Contextual Fear Conditioning 
 In this experiment we tested whether the administration of the GABAB agonist 
baclofen or the GABAB antagonist phaclofen throughout the entirety of the Pavlovian 
delay or trace CCF protocols would alter performance in the tasks.  For the delay CCF 
conditioning protocol, one-way ANOVA of each group’s average proportion time 
freezing during the first two minutes of training revealed a significant difference between 
the groups (F2,27=12.31, p<0.01; Tukey post-hoc revealed a significant difference 
between saline and baclofen only, p<0.01; see Figure 2a).  There were no significant 
differences between groups during the last two minutes of training (F2,27=0.263, p>0.05), 
demonstrating that each group responded equivalently to the training.  Paired t-test 
analyses of PreCSUS freezing compared to PostCSUS freezing revealed that each group 
significantly increased freezing during the last two minutes of training (saline: t9=-
30.594, p<0.01; baclofen: t9=-4.979, p<0.01; phaclofen: t9=-17.321, p<0.01).   
For the trace CCF conditioning protocol, one-way ANOVA of each group’s 
average proportion time freezing during the first two minutes of training revealed no 
significant differences between groups (F2,27=3.254, p>0.05; see Figure 2b).  There were 
no significant differences during the last two minutes of training (F2,27=1.259, p>0.05), 
demonstrating that each group responded equivalently to the training.  Paired t-test 
analyses of PreCSUS freezing compared to PostCSUS freezing revealed that each group 
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significantly increased freezing during the last two minutes training (saline:  t9=-20.846, 
p<0.01; baclofen:  t9=-5.596, p<0.01; phaclofen:  t9=-11.063, p<0.01). 
 
 
Figure 2.  Experiment 1 Day 1 Training – Proportion of time freezing (±SEM) was 
determined for the first two minutes of training (PreCSUS) and the last two minutes of 
training (PostCSUS) for delay (a) and trace (b) CCF conditioning.  # = Significantly 
different from saline, p<0.05; * = Significant difference between PreCSUS freezing and 
PostCSUS freezing, p<0.05 
 
 
 Cued fear was tested on Days 2, 4, and 6 in the altered context chamber to 
determine the strength of the association between the tone (the CS) and the mild foot-
shock (the US).  For the delay CCF conditioning protocol, repeated measures ANOVA 
revealed significant within-group effects for Days 2 (F4,108=11.49, p<0.01), 4 
(F4,108=6.862, p<0.01), and 6 (F4,108=10.251, p<0.01); only on Day 4 a significant 
difference between groups appeared (F2,27=3.851, p<0.05).  Although Tukey post-hocs 
revealed no significant differences compared to saline, the baclofen group did show a 
trend of increased freezing.  A one-way ANOVA revealed no significant differences 
between groups during the reminder CS that was administered in the original training 
context (F2,27=2.637, p>0.05; see Figure 3a). 
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 For the trace CCF conditioning protocol, repeated measures ANOVA revealed 
significant within-group effects for Days 2 (F4,108=23.22, p<0.01), 4 (F4,108=3.585, 
p<0.01), and 6 (F24,108=4.699, p<0.01; see Figure 3b).  Only on Day 4 a significant 
difference between groups appeared (F2,27=5.622, p<0.01), and Tukey post-hocs revealed 
baclofen froze significantly more than saline (p<0.01).  A one-way ANOVA revealed no 
significant differences between groups during the reminder CS that was administered in 
the original training context (F2,27=0.883, p>0.05). 
 Contextual Fear was tested on Days 3, 5, and 7; the animals were placed back in 
the original training context and observed for 10 minutes, with no CS or US 
presentations.  For the delay CCF conditioning protocol, repeated measures ANOVA 
revealed significant within-group effects only on Days 3 (F4,108=2.992, p<0.05) and 7 
(F4,108=5.815, p<0.01), and significant differences between groups only on Day 5 
(F2,27=7.053, p<0.01; Tukey post-hocs revealed a significant difference between saline 
and baclofen, p<0.05).  A one-way ANOVA revealed no significant differences between 
groups in the two-minute interval after the reminder CS-US pairing (PostReminder; 
F2,27=0.551, p>0.05; see Figure 4a). 
 For the trace CCF conditioning protocol, repeated measures ANOVA revealed 
significant within-group effects only on Days 3 (F4,108=5.186, p<0.01) and 7 
(F4,108=2.547, p<0.05), and significant differences between groups only on Day 5 
(F2,27=4.045, p<0.05; Tukey post-hocs revealed a significant difference between saline 
and baclofen, p<0.05).  A one-way ANOVA revealed no significant differences between 
groups in the two-minute interval after the reminder CS-US pairing (PostReminder; 
F2,27=1.069, p>0.05; see Figure 4b).  
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Figure 3.  Experiment 1 Cued Fear Extinction – Proportion time freezing (±SEM) was 
determined for the first two minutes the animal was placed into the altered context, as 
well as during each one minute presentation of the CS for delay (a) and trace (b) CCF 
conditioning.  * = Significantly different from saline, p<0.05; # = Significant within-
group effects, p<0.05 
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Figure 4.  Experiment 1 Contextual Fear Extinction – Proportion time freezing (±SEM) 
was determined for each block of two minutes in the original training chamber for delay 
(a) and trace (b) CCF conditioning.  * = Significantly different from saline, p<0.05; # = 
Significant within-group effects, p<0.05 
 
 
Sensory Testing 
To determine whether the GABAB agonist baclofen or the GABAB antagonist 
phaclofen altered the way the animals detected the stimuli, we tested their startle 
amplitudes to white noise bursts at several decibel levels.  For the delay CCF conditioned 
animals, one-way ANOVA revealed no significant differences between groups at any 
decibel level (p>0.05; see Figure 5a).  For the trace CCF conditioned animals, one-way 
ANOVA revealed significant differences between groups at 90 dB (F2,117=5.466, p<0.01; 
Tukey post-hoc revealed that baclofen was significantly decreased compared to saline), 
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100 dB (F2,117=12.726, p<0.01; Tukey post-hoc revealed that both baclofen and phaclofen 
were significantly decreased compared to saline), 110 dB (F2,117=4.828, p<0.05; Tukey 
post-hoc revealed that baclofen was significantly decreased compared to saline), and 120 
dB (F2,117=5.428, p<0.01; Tukey post-hoc revealed that baclofen was significantly 
decreased compared to saline; see Figure 5b). 
 
 
Figure 5.   Experiment 1 Startle Amplitude – Average startle amplitude (±SEM) to 
several decibel levels for delay (a) and trace (b) CCF conditioned animals.  * = 
Significantly different from saline 
 
 
Analgesia Testing 
 In order to ensure that the administration of the GABAB agonist baclofen or the 
GABAB antagonist phaclofen did not alter the way the animals perceived pain, the tail 
flick test was used to measure analgesia.  For the delay CCF conditioned animals, one-
way ANOVA did not reveal any significant differences between the groups (F2,27=2.653, 
p>0.05; see Figure 6a).  For the trace CCF conditioned animals, one-way ANOVA did 
not reveal any significant differences between the groups (F2,27=3.126, p>0.05; see Figure 
6b). 
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Figure 6.  Experiment 1 Tail Flick Latency – Average tail flick latency (±SEM) for delay 
(a) and trace (b) CCF conditioned animals.  
 
 
SDS-Page Western Blotting 
For the delay CCF conditioned animals, one-way ANOVA of the normalized 
band densities compared to an average of the saline group revealed a significant decrease 
in the GABAB1b receptor subunit in the hippocampus in the phaclofen group compared to 
the saline group (F2,27=4.576, p<0.05; Tukey post-hoc revealed a significant difference 
between saline and phaclofen, p<0.05; see Figure 7a), but no significant effects compared 
to the saline group for the GABAB1a receptor subunit (F2,27=4.005, p<0.05; Tukey post-
hoc did not reveal any significant comparisons with saline).   While non-significant, there 
was a trend of increased protein levels for both GABAB1 subunits in the baclofen group.  
While no significant differences were found between the groups for GABAB1 receptor 
subunits in the cortex (see Figure 7e), there was a trend of decreased protein levels in the 
phaclofen group.  Again, while non-significant, the baclofen group showed a slight trend 
of an increase in both receptor subunit protein levels.   
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Figure 7.  Experiment 1 GABAB1 Western Blot Results – Average protein level (±SEM) 
in proportion to the saline control group for delay (a, b, e, f, i, j) and trace (c, d, g, h, k, l) 
CCF conditioned animals in hippocampal (a, c), cortical (e, g), and amygdalar (i, k) 
tissue, and representative western blot images (b, d, f, h, j, l).  * = Significantly different 
from saline, p<0.05 
 
 
 While no significant differences were found between the groups for GABAB1 
receptor subunits in the cortex (see Figure 7e), there was a trend of decreased protein 
levels in the phaclofen group.  Again, while non-significant, the baclofen group showed a 
slight trend of an increase in both receptor subunit protein levels.  Further, no significant 
differences were found in the amygdala for the GABAB1 receptor subunits (see Figure 
7i); though, again there was an increase in the GABAB1b subunit in the baclofen-treated 
group, as well as a decrease in the GABAB1b subunit in the phaclofen-treated group. 
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 For the trace CCF conditioned animals, there was a non-significant decrease in 
hippocampal GABAB1 protein in the baclofen and phaclofen groups compared to the 
saline group (see Figure 7c), though this difference was not evident in the cortex (see 
Figure 7g).  Indeed, there is a slight increase in the GABAB1a protein in the baclofen-
treated group.  While not significant, there is an increase in both GABAB1 subunit 
proteins for the phaclofen-treated group in the amygdala (see Figure 7k), and a decrease 
in the GABAB1b subunit for the baclofen-treated group. 
Further, in the delay CCF conditioned animals, there was a significant decrease of 
the GABAB2 receptor subunit in the phaclofen group compared to the saline group in the 
hippocampus (F2,27=9.374, p<0.01; Tukey post-hoc comparison between phaclofen and 
saline p<0.01; see Figure 8a) and a significant reduction of the GABAB2 receptor subunit 
in both the baclofen and phaclofen groups in the cortex (F2,27=15.187, p<0.01; Tukey 
post-hoc comparisons for saline versus both baclofen and phaclofen p<0.01; see Figure 
8e).  No differences were found in the amygdala for the GABAB2 receptor subunit (see 
Figure 8i). 
For the trace CCF conditioned animals, there were no changes in the GABAB2 
receptor subunit in hippocampal tissue, but there was a trend of decreased protein levels 
in the baclofen group (see Figure 8c); no differences between groups in GABAB2 protein 
levels were seen in the cortex either (see Figure 8g), although there was a slight increase 
in the phaclofen-treated group.  In the amygdala, there was a significant increase in the 
GABAB2 receptor protein in the baclofen-treated group (F2,19=5.58, p<0.05; Tukey post-
hoc comparison for saline versus baclofen, p<0.01) , and a non-significant increase in the 
phaclofen group (see Figure 8k). 
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Figure 8.  Experiment 1 GABAB2 Western Blot Results – Average protein level (±SEM) 
in proportion to the saline control group in delay (a, b, e, f, i, j) and trace (c, d, g, h, k, l) 
CCF conditioned animals in hippocampal (a, c), cortical (e, g), and amygdalar (i, k) 
tissue, and representative western blot images (b, d, f, h, j, l).  * = Significantly different 
from saline, p<0.05 
 
 
Interestingly, a commonly implicated GABAA receptor subunit (GABAAα5) in 
learning and memory was not significantly changed between the delay CCF conditioned 
groups in the hippocampus (see Figure 9a) or in the cortex (see Figure 9e).  Though non-
significant, there was a slight increase in the protein levels in the baclofen group for the 
hippocampal tissue, and a slight decrease in the protein levels for both the baclofen and 
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phaclofen groups in the cortical tissue.  A similar result was found for the trace CCF 
conditioned groups; the GABAAα5 receptor subunit was not significantly changed 
between the groups in the hippocampus (see Figure 9c) or in the cortex (see Figure 9g).  
There was a slight increase in the protein in the cortex for both the baclofen and 
phaclofen treated groups, but only a slight increase in the protein in the baclofen treated 
group in the hippocampus. 
 
 
Figure 9.  Experiment 1 GABAAα5 Western Blot Results – Average protein level (±SEM) 
in proportion to the saline control group in delay (a, b, e, f) and trace (c, d, g, h) CCF 
conditioned animals in hippocampal (a, c) and cortical (e, g) tissue, and representative 
western blot images (b, d, f, h). 
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Experiment 2 – GABAB Ligands Administered After Cued and Contextual Fear 
Conditioning Training 
Cued and Contextual Fear Conditioning 
In order to verify that the results achieved in Experiment 1 were not a result of the 
GABAB ligands altering the way the animals acquired the task, we tested in Experiment 2 
whether administering baclofen (GABAB agonist) or phaclofen (GABAB antagonist) 24 
hours after all groups had been trained in and acquired either the delay or trace CCF 
conditioning task would alter performance during extinction.  For the delay CCF 
conditioned animals, one-way ANOVA of each group’s average proportion time freezing 
during the first two minutes of training could not be performed because no freezing was 
exhibited by any group; thus, there is no significant difference between the groups before 
training.  Additionally, there were no significant differences during the last two minutes 
of training (F2,27=1.588, p>0.05), demonstrating that each group responded equivalently 
to the training.  Paired t-test analyses of freezing during the first two minutes of training 
(PreCSUS) compared to the last two minutes of training (PostCSUS) revealed that each 
group significantly increased freezing after training (saline: t9=-15.523, p<0.01; baclofen: 
t9=-37.315, p<0.01; phaclofen: t9=-26.022, p<0.01; see Figure 10a).   
For the trace CCF conditioned animals, the data of one baclofen animal was 
removed due to complications during the experiment, so saline n=10, baclofen n=9, and 
phaclofen n=10.  One-way ANOVA of each group’s average proportion time freezing 
during the first two minutes of training revealed no significant differences between 
groups (F2,26=1.121, p>0.05).  Additionally, there were no significant differences during 
the last two minutes of training (F2,26=0.783, p>0.05), demonstrating that each group 
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responded equivalently to the training.  Paired t-test analyses of freezing during the first 
two minutes of training compared to the last two minutes of training revealed that each 
group significantly increased freezing after training (saline: t9=-40.088, p<0.01; baclofen: 
t8=-12.529, p<0.01; phaclofen: t9=-15.377, p<0.01; see Figure 10b). 
 
 
Figure 10.  Experiment 2 Day 1 Training – Proportion of time freezing (±SEM) was 
determined for the first two minutes of training (PreCSUS) and the last two minutes of 
training (PostCSUS) for delay (a) and trace (b) CCF conditioning. * = Significant 
difference between PreCSUS freezing and PostCSUS freezing, p<0.05 
 
 
Cued fear was tested on Days 2, 4, and 6 in the altered context chamber to 
determine the strength of the association between the CS and US.  For the delay CCF 
conditioning protocol, repeated measures ANOVA revealed significant within-group 
effects for Days 2 (F4,108=12.261, p<0.01), 4 (F4,108=7.586, p<0.01), and 6 (F4,108=6.603, 
p<0.01; see Figure 11a), as well as significant between group effects for Days 2 
(F2,27=9.351, p<0.01), 4 (F2,27=14.726, p<0.01), and 6 (F2,27=4.851, p<0.05).  Tukey post-
hocs revealed baclofen froze significantly more than saline (p<0.05 for all days).  A one-
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way ANOVA revealed no significant differences between groups during the reminder CS 
that was administered in the original training context (F2,27=.159, p>0.05). 
For the trace CCF conditioning protocol, repeated measures ANOVA revealed 
significant within-group effects for Days 2 (F4,104=15.707, p<0.01), 4 (F4,104=4.808, 
p<0.01), and 6 (F4,104=7.978, p<0.01; see Figure 11b), as well as significant between 
group effects for Days 2 (F2,26=5.338, p<0.05) and 4 (F2,26=7.579, p<0.01).  Tukey post-
hocs revealed baclofen froze significantly more than saline (p<0.05 for both days).  A 
one-way ANOVA revealed no significant differences between groups during the 
reminder CS that was administered in the original training context (F2,26=0.511, p>0.05). 
 Contextual Fear was tested on Days 3, 5, and 7; the animals were placed back in 
the original training context and observed for 10 minutes, with no CS or US 
presentations.  Repeated measures ANOVA for the delay CCF conditioned animals 
revealed significant within-group effects only on Days 3 (F4,108=14.235, p<0.01), 5 
(F4,108=3.288, p<0.05), and 7 (F4,108=5.606, p<0.01), and significant differences between 
groups only on Day 5 (F2,27=18.898, p<0.01; Tukey post-hocs revealed a significant 
difference between saline and baclofen, p<0.01).  A one-way ANOVA revealed no 
significant differences between groups in the two-minute interval after the reminder CS-
US pairing (F2,27=0.099, p>0.05; see Figure 12a).  For the trace CCF conditioning 
protocol, repeated measures ANOVA revealed significant within-group effects only on 
Days 3 (F4,104=7.034, p<0.01), 5 (F4,104=3.233, p<0.05), and 7 (F4,104=6.356, p<0.01), and 
significant differences between groups only on Day 5 (F2,26=16.531, p<0.01; Tukey post-
hocs revealed a significant difference between saline and baclofen, p<0.01).  A one-way 
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ANOVA revealed no significant differences between groups in the two-minute interval 
after the reminder CS-US pairing (F2,26=0.46, p>0.05; see Figure 12b). 
 
 
Figure 11.  Experiment 2 Cued Fear Extinction – Proportion time freezing (±SEM) was 
determined for the first two minutes the animal was placed into the altered context, as 
well as during each one minute presentation of the CS for delay (a) and trace (b) CCF 
conditioning.  * = Significantly different from saline, p<0.05; # = Significant within-
group effects, p<0.05 
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Figure 12.  Experiment 2 Contextual Fear Extinction – Proportion time freezing (±SEM) 
was determined for each block of two minutes while the animal was in the original 
training chamber for the delay (a) and trace (b) CCF conditioning protocol.  * = 
Significantly different from saline, p<0.05; # = Significant within-group effects, p<0.05 
 
 
Sensory Testing 
To ensure that the GABAB agonist baclofen or the GABAB antagonist phaclofen 
did not alter the way the animals detected the stimuli, we tested their startle amplitudes to 
white noise bursts at several decibel levels.  For delay CCF conditioned animals, one-way 
ANOVA revealed no significant differences compared to saline (p>0.05; see Figure 13a).  
Likewise for the trace CCF conditioned animals, one-way ANOVA did not reveal a 
significant difference between groups (p>0.05; see Figure 13b). 
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Figure 13.  Experiment 2 Startle Amplitude – Average startle amplitude (±SEM) to 
several decibel levels for delay (a) and trace (b) CCF conditioned animals.   
 
 
Analgesia Testing 
To determine that neither the GABAB agonist baclofen nor the GABAB antagonist 
phaclofen altered the way the animals perceived pain, the tail flick test was used to 
measure nociception.  For the delay CCF conditioned animals, one-way ANOVA did not 
reveal any significant differences between the groups (F2,27=0.769, p>0.05; see Figure 
14a).  For the trace CCF conditioned groups, one-way ANOVA did reveal a significant 
difference between the groups (F2,26=9.122, p<0.01); Tukey post-hocs revealed that 
baclofen had a significantly higher tail flick latency than saline (p<0.01; see Figure 14b). 
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Figure 14.  Experiment 2 Tail Flick Latency – Average tail flick latency (±SEM) for 
delay (a) and trace (b) CCF conditioned animals.  * = Significantly different from saline 
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CHAPTER 5 
SUMMARY, CONCLUSIONS, AND FUTURE DIRECTIONS 
 While the administration of phaclofen did not alter performance in either the 
delay or trace CCF conditioning protocol compared to saline, baclofen administration did 
produce a consistent extinction deficit in both experiments.  This deficit is evident in the 
lack of reduced freezing by the second cued (Day 4) and contextual (Day 5) extinction 
sessions compared to the controls.  The saline and phaclofen-treated groups demonstrate 
typical extinction behavior as demonstrated by the reduction in freezing to both the tone 
and original training chamber over time as each is presented continually without further 
US presentations.  This finding is surprising considering we had originally hypothesized 
that the administration of baclofen would enhance extinction (as evidenced by an increase 
in the rate of reduction in freezing) based on the current literature and theory of 
extinction that suggests that extinction is largely guided by inhibitory mechanisms (see 
Makkar, Zhang, & Cranney, 2010).  Possibly because the bulk of the data are derived 
from research that used compounds that target GABAA receptors, GABAB-driven 
alterations to extinction may just need to be characterized further.   
Additionally, we hypothesized that phaclofen administration would impair 
extinction, which would be indicated by a lack of reduced freezing.  Instead, the 
phaclofen-treated animals in both experiments were indistinguishable from the saline 
control groups.  We also hypothesized that any behavioral differences would be more 
evident in the trace CCF conditioning protocol due to its increased difficulty compared to 
the delay task.  However, all of the behavioral differences in the experiments mirror each 
other regardless of the protocol in which the animals were trained.  
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We also originally hypothesized that baclofen administration would impair the 
acquisition of either delay or trace CCF task, as would be demonstrated by a reduction in 
proportion time freezing during the first test of cued (Day 2) or contextual (Day 3) fear.  
However, the administration of baclofen did not reduce freezing in either experiment at 
any point during Days 2 or 3.  We also hypothesized that the administration of phaclofen 
would enhance acquisition of the tasks, which would be indicated by increased freezing 
throughout Days 2 or 3.  Again, we saw no effect of the ligand during those two days. 
While the animals treated with baclofen before training in both the delay and trace 
CCF conditioning protocols in Experiment 1 did show an increase in freezing behavior 
before any CS-US presentations, this difference was not present by the beginning of the 
session on Day 2, and did not reappear throughout the remainder of the experiment.  
Similarly, while freezing was increased during the first day of administration (Day 2) for 
the baclofen-treated animals in Experiment 2, these differences disappeared by the 
beginning of the second day of administration (Day 3).  Therefore, any differences seen 
during Days 4 and 5 cannot be attributed to these initial drug effects. 
 Further, even though one of the baclofen-treated groups exhibited differences 
compared to the control group in each of the control tests, these differences cannot 
account for the extinction deficits we see in the experiments.  For instance, a reduced 
startle response would suggest that administration of baclofen impaired detection of the 
CS.  Additionally, an increase in tail flick latency would suggest that baclofen-treated 
animals had impaired nociception.  Both of these cases should manifest as impaired 
acquisition (decreased freezing during Days 2 or 3 compared to controls) or enhanced 
extinction (an increase in the rate of the reduction of freezing during Days 4 or 5 
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compared to controls).  However, all of the baclofen-treated groups showed no 
acquisition deficits and demonstrated extinction deficits.  Therefore, any differences seen 
during Days 4 and 5 cannot be explained by altered CS detection or deceased 
nociception.  
These experiments, therefore, demonstrate that baclofen impairs the extinction of 
both cued and contextual fear in both delay and trace CCF protocols.  Extinction can be 
seen in the saline- and phaclofen-treated groups, as their freezing decreases similarly 
during Days 4 and 5.  The baclofen-treated animals, however, lack this same reduction in 
freezing, demonstrating that they are not learning that the CS and the original context no 
longer predict the US.    
 Interestingly, the administration of either GABAB ligand produced task-dependent 
changes in the tissue.  For instance, the baclofen-treated group that was trained in the 
delay CCF conditioning protocol showed a non-significant increase in the GABAB1 
subunits in the hippocampus, but in the trace CCF conditioned group, there was a non-
significant reduction in the same tissue.  Similarly, for the GABAB1 subunits in the 
cortex, the delay CCF conditioned phaclofen group showed a non-significant reduction, 
whereas the trace CCF conditioned phaclofen group demonstrated an increase.  We even 
found a drug-by-task difference in the amygdala; in the delay CCF conditioning protocol, 
the baclofen-treated group had increased levels, but the phaclofen-treated group had 
decreased levels of the GABAB1b receptor subunit.  However this trend was reversed in 
the trace CCF conditioned groups, the baclofen-treated group had decreased levels, and 
the phaclofen-treated group had increased levels of GABAB1b.   
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This pattern of task-dependent changes is evident for the GABAB2 receptor 
subunit, as well.  In the hippocampus of the delay CCF conditioned phaclofen-treated 
group, there is a significant reduction, but there is no evidence of a decrease in the protein 
in the trace CCF conditioned phaclofen group.  Further, in the cortex, both the baclofen 
and phaclofen groups from the delay CCF conditioned animals show a significant 
reduction of the GABAB2 protein, but these differences are non-existent in the trace CCF 
conditioned groups.  Finally, while there were no changes to the protein in the amygdala 
of the delay CCF conditioned groups, there was a significant increase in the baclofen-
treated group and a trend of increased GABAB2 in the phaclofen-treated group of the 
animals trained in the trace CCF conditioning protocol.   
 These task-dependent protein changes do not, however, extend to other 
GABAergic proteins.  The GABAAα5 receptor, a subunit that has the ability to alter 
learning and memory (Collinson et al., 2002), was not significantly changed between 
groups in the hippocampus or the cortex in either delay or trace CCF conditioned groups.  
Yee et al. (2004) demonstrated that a GABAAα5 knockdown mutant was resistant to 
extinction; the extinction deficits seen in these experiments, therefore, are not tied to 
changes in this particular receptor subunit. 
 While some of these protein changes do help to explain the baclofen-induced 
extinction deficits in both the delay and trace CCF conditioning tasks, others do not.  
Specifically, because the current theory suggests that increased inhibitory action 
facilitates extinction, the significant increase of GABAB2 in the amygdala of the 
baclofen-treated animals that were trained in the trace CCF conditioning protocol does 
not support the behavioral extinction deficit.  However, the significant reduction of the 
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same protein in the cortex of the delay CCF conditioned animals in the baclofen group 
does support the behavioral data and fits with the current literature.  Additionally, even 
though the administration of phaclofen did not alter behavior in either delay or trace CCF 
conditioning protocol compared to the saline group, it is very interesting that there are 
instances of altered protein levels in the these groups in several brain regions.  
Furthermore, we hypothesized that we would find more differences in the trace CCF 
conditioned groups because the task is more difficult than the delay protocol, however the 
most number of significant differences in protein levels were found in the groups that 
were trained in the delay CCF conditioning protocol.   
In the trace CCF conditioned baclofen-treated group, there was a non-significant 
decrease in the hippocampus in both GABAB1 subunits compared to the saline group.  
The GABAB1a receptor subunits are thought to mediate presynaptic inhibition, and the 
typical effect of baclofen is to presynaptically decrease neurotransmitter release by 
decreasing calcium conductance (Misgeld, Bijak, & Jarolimek, 1995).  Possibly by 
increasing the amount of presynaptic inhibition (that leads to decreased neurotransmitter 
release) via the GABAB receptors, the receptors were down regulated to decrease the 
inhibitory effects.  The effect of presynaptic inhibition on behavior depends on the 
neurotransmitter that was prevented from being released.  Since the administration 
baclofen impaired extinction, it is possible that hippocampal glutamate is being affected.  
Indeed, Vigot et al. (2006) found that the GABAB1a receptor subunit localized at 
glutamatergic terminals in hippocampal tissue, and GABAB1a knockout mice 
demonstrated impaired LTP – a glutamatergic-dependent function.  GABAB1b subunits 
are typically found on postsynaptic neurons, and the decrease in these subunits actually 
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follows theoretical assumptions.  Since baclofen acts to increase inhibition of the neuron, 
it makes sense that the neuron would down-regulate this protein to try to maintain 
homeostasis. 
Phaclofen acts by antagonizing the GABAB receptor complex, so these decreased 
protein levels are paradoxical.  A blocked and nonfunctional receptor should, 
theoretically, lead to an up-regulation of the receptor to help bring cellular functioning 
back to baseline.  It is possible that up-regulating GABA receptors in certain brain 
regions poses risks to the cell, so the neuron may need to make the necessary changes by 
down-regulating the GABAB receptor complex and then use an alternative method to 
increase cellular inhibition.  An alternative to increasing GABAB receptors could be 
increasing the inward-rectifying potassium channels (GIRK) associated with the GABAB 
receptors.  
What is interesting is that phaclofen administration did not alter GABAB1 
receptors in the cortex, but there was a significant reduction in the GABAB2 subunits in 
the cortex.  The GABAB2 subunit is the G-protein coupled receptor subunit and is the 
component needed to shuttle the receptor complex from the endoplasmic reticulum to the 
cell surface.  Considering the SDS-PAGE western blots completed only detect total 
protein levels and not cell-surface-expressed protein levels, it is possible that these 
differences may disappear if an assay for surface-expressed proteins were done.  Further, 
it is entirely possible that other differences between the control and baclofen-treated 
groups are being occluded by this western blotting procedure only being able to detect 
total protein levels.  Future experiments could utilize cell surface biotinylation assays, 
quantitative polymerase chain reaction assays to examine mRNA differences, or western 
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blots for phosphorylation targets like serine 783 that indicate cell-surface expressed 
GABAB receptors.  Because the tissue analyses strongly indicate a task-dependent change 
in the proteins, it is also possible that more neurological resources are needed for the 
trace CCF conditioning task compared to the delay task, thus fewer alterations in the 
GABAergic proteins are necessary. 
It is also possible that the administration of baclofen actually did alter these 
proteins.  If the changes occurred earlier during the behavioral task than when we 
collected tissue, then we may have missed the ability to detect these differences.  Based 
on the behavioral impairments, it was surprising not to see more protein changes in the 
baclofen-treated groups.  Future experiments could examine the effect of baclofen 
administration on these protein targets at different time points throughout the delay and 
trace CCF conditioning protocols. 
While the tissue analyses do not necessarily correspond to how typical G-protein 
coupled receptors (GPCRs) respond to agonist and antagonist mediation, they do fit in 
nicely with several in vitro GABAB receptor studies.  For instance, the most robust 
changes to the GABAB1 subunits were specifically to the preferentially postsynaptic 
GABAB1b isoform.  Wetherington and Lambert (2002) demonstrated that GIRK-
associated postsynaptic GABAB receptors rapidly desensitized to agonist treatment, 
whereas GIRK-associated presynaptic GABAB receptors failed to desensitize even after 
24 hours of agonist treatment.  Therefore, it is possible that presynaptic GABAB receptors 
are less sensitive to prolonged ligand treatment.  Other research has demonstrated that 
GABAB receptors do no internalize in response to agonist treatment (Perroy et al., 2003; 
Fairfax et al., 2004; Mutneja et al., 2005), but that agonist treatment does produce a 
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decrease in cell surface-expressed receptors (Fairfax et al., 2004).  These data suggest 
that GABAB receptors do not respond to ligand treatment like typical GPCRs.  Couve, 
Moss, and Pangalos (2007) suggest that GABAB receptors may utilize a “new receptor 
model in which the levels of GABAB receptors are not correlated with receptor activity,” 
and this conclusion can be logically extended to include behavioral activity, as well. 
A consideration for future experiments would be the dose and route of 
administration of the compounds used in the current study.  It is possible that the current 
dose of phaclofen is too low to effect a change in behavior, even if it is altering protein 
levels in several brain regions.  A study of the effects of subcutaneous administration of 
these compounds could elucidate other effects on learning and memory.  Additionally, 
since the current study simply examined the effects of a daily system injection of either 
baclofen or phaclofen on behavior, it would be very interesting to examine the effects of 
continual transcranial infusion of these compounds to specific brain regions.  Further, by 
infusing the compounds transcranially, we could gain region specificity and would be 
able to examine the influence of altered GABAergic tone in a particular brain region on 
learning and extinction. 
 An open-field test would be an additional control test to consider for future 
experiments.  This test would measure the distance an animal travels in a non-aversive 
environment; any differences in locomotion caused by the drugs administered would be 
easily detected.  This control would best be utilized before the onset of the behavioral 
task. 
 Finally, tasks that utilize varying amounts of stress would also be interesting 
future experiments.  Perhaps the drugs used would differentially affect performance 
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based on how stressed the animal is; the amount of stress may also relate to brain 
structures being used to complete a behavioral task.  For instance, appetitive conditioning 
may not be mediated by the amygdala to the same degree as fear conditioning.  It is 
possible that other tasks may be more sensitive to the effects caused by the ligands used 
in the current study.   
 Overall, the behavioral results of these experiments are quite consistent and 
demonstrate that baclofen administration hinders the extinction of both cued and 
contextual fear associations.  While the tissue analyses do not necessarily demonstrate 
typical G-protein coupled receptor response to ligand administration, there are some very 
interesting protein level differences that strongly indicate a task-dependent change due to 
the ligands.  Additionally, these results suggest that GABAB ligands alter behavior and 
cellular components differentially, meriting further research into these individual 
components.  While rather interesting, these data need to be further clarified in future 
experiments to elucidate not only how altered GABAB receptor function affects the brain 
regions associated with fear conditioning, but to also determine if decreased GABAB 
receptor function can affect cued and contextual fear behavior.  
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